No. 23-395
Alliance for Hippocratic Medicine, et al. v. Food and Drug Administration, et al.
Amici (3)
Experienced Counsel
Tags: abortion abortion-medication administrative-procedure-act drug-regulation fda fda-approval generic-drugs medical-safety mifepristone subpart-h
Key Terms:
AdministrativeLaw Environmental Patent TradeSecret Privacy JusticiabilityDoctri
AdministrativeLaw Environmental Patent TradeSecret Privacy JusticiabilityDoctri
Latest Conference:
2023-12-08
Question Presented (from Petition)
1. Whether Cross-Petitioners' challenge to FDA's 2000 mifepristone approval is timely.
2. Whether FDA's 2000 approval of mifepristone under Subpart H, which applies only to drugs that "treat[] serious or life-threatening illnesses," 21 C.F.R. 314.500, and FDA's subsequent approval of generic mifepristone were unlawful.
Question Presented (AI Summary)
Whether Cross-Petitioners' challenge to FDA's 2000 mifepristone approval is timely
Docket Entries
2023-12-13
Petition DENIED.
2023-11-28
Reply of petitioners Alliance for Hippocratic Medicine, et al. filed. (Distributed)
2023-11-21
DISTRIBUTED for Conference of 12/8/2023.
2023-11-15
Brief amicus curiae of Human Coalition filed.
2023-11-15
Brief amici curiae of 109 Members of Congress filed.
2023-11-13
Brief amici curiae of Mississippi, et al. filed.
2023-11-07
Brief of respondent Danco Laboratories, LLC in opposition filed.
2023-11-07
Brief of Federal Cross-Respondents in opposition filed.
2023-10-12
Petition for a writ of certiorari filed. (Response due November 15, 2023)
Attorneys
109 Members of Congress
Steven Henry Aden — Americans United for Life, Amicus
Alliance for Hippocratic Medicine, et al.
Erin Morrow Hawley — Alliance Defending Freedom, Petitioner
Danco Laboratories, LLC
Jessica Lynn Ellsworth — Hogan Lovells US, LLP, Respondent
Human Coalition
State of Mississippi, et al.
United States
Elizabeth B. Prelogar — Solicitor General, Respondent